Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment

Predictive imaging marker of bevacizumab efficacy: perfusion MRI: Table 1.

(2015) Whitney B. Pope   NEURO-ONCOLOGY

Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial

(2015) Kathleen M. Schmainda et al.   NEURO-ONCOLOGY

Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma

(2015) Philipp Kickingereder et al.   NEURO-ONCOLOGY

Repeatability of Cerebral Perfusion Using Dynamic Susceptibility Contrast MRI in Glioblastoma Patients

(2015) Kourosh Jafari-Khouzani et al.   Translational Oncology

Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma

(2014) K. M. Schmainda et al.   NEURO-ONCOLOGY

Standardization of relative cerebral blood volume (rCBV) image maps for ease of both inter- and intrapatient comparisons

(2010) Devyani Bedekar et al.   MAGNETIC RESONANCE IN MEDICINE